Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 146

1.

Ranibizumab in myopic choroidal neovascularization: the 12-month results from the REPAIR study.

Tufail A, Narendran N, Patel PJ, Sivaprasad S, Amoaku W, Browning AC, Osoba O, Gale R, George S, Lotery AJ, Majid M, McKibbin M, Menon G, Andrews C, Brittain C, Osborne A, Yang Y.

Ophthalmology. 2013 Sep;120(9):1944-5.e1. doi: 10.1016/j.ophtha.2013.06.010. No abstract available.

2.

Myopic choroidal neovascularization.

Ruiz-Moreno JM, López-Gálvez MI, Donate J, Gomez-Ulla F, García-Arumí J, García-Layana A, Sellés I, Reche J, Montero JA, Pazos B, Zapata MA, Pastor JC.

Ophthalmology. 2011 Dec;118(12):2521-3. doi: 10.1016/j.ophtha.2011.07.029. No abstract available.

PMID:
22136676
3.

Intravitreal bevacizumab in myopic neovascular membranes: 24-month results.

Ruiz-Moreno JM, López-Gálvez MI, Montero Moreno JA, Pastor Jimeno JC.

Ophthalmology. 2013 Jul;120(7):1510-1.e1. doi: 10.1016/j.ophtha.2013.03.006. No abstract available.

PMID:
23823510
4.
5.

Intravitreal ranibizumab versus bevacizumab for treatment of myopic choroidal neovascularization.

Iacono P, Parodi MB, Papayannis A, Kontadakis S, Sheth S, Cascavilla ML, Bandello F.

Retina. 2012 Sep;32(8):1539-46. doi: 10.1097/IAE.0b013e31826956b7.

PMID:
22922846
6.

Three versus one intravitreal bevacizumab injections as initial protocol to treat myopic choroidal neovascularization.

Ruiz-Moreno JM, Montero JA, Arias L, Araiz J, Gomez-Ulla F, Silva R, Piñero DP.

Acta Ophthalmol. 2012 Feb;90(1):e82-3. doi: 10.1111/j.1755-3768.2010.02070.x. Epub 2011 Apr 6. No abstract available.

7.

A new treatment algorithm for the management of myopic choroidal neovascularization using intravitreal ranibizumab.

Iacono P, Parodi MB, Papayannis A, La Spina C, Varano M, Bandello F.

Acta Ophthalmol. 2015 Sep;93(6):e519-20. doi: 10.1111/aos.12677. Epub 2015 Apr 1. No abstract available.

8.

Intravitreal ranibizumab for choroidal neovascularization complicating pathologic myopia.

Lalloum F, Souied EH, Bastuji-Garin S, Puche N, Querques G, Glacet-Bernard A, Coscas G, Soubrane G, Leveziel N.

Retina. 2010 Mar;30(3):399-406. doi: 10.1097/IAE.0b013e3181bcef24.

PMID:
20038864
9.

Long-term variable outcome of myopic choroidal neovascularization treated with ranibizumab.

Cohen SY, Nghiem-Buffet S, Grenet T, Dubois L, Ayrault S, Fajnkuchen F, Delahaye-Mazza C, Quentel G, Tadayoni R.

Jpn J Ophthalmol. 2015 Jan;59(1):36-42. doi: 10.1007/s10384-014-0363-z. Epub 2014 Nov 22.

PMID:
25416566
10.

Intravitreal ranibizumab for the treatment of choroidal neovascularizations associated with pathologic myopia: a prospective study.

Pasyechnikova NV, Naumenko VO, Korol AR, Zadorozhnyy OS, Kustryn TB, Henrich PB.

Ophthalmologica. 2015;233(1):2-7. doi: 10.1159/000369397. Epub 2014 Dec 6.

PMID:
25501802
11.

Intravitreal injection of 2.5 mg bevacizumab for treatment of myopic choroidal neovascularization in treatment-naive cases: a 2-year follow-up.

Chen CH, Wu PC, Chen YJ, Liu YC, Kuo HK.

J Ocul Pharmacol Ther. 2011 Aug;27(4):395-400. doi: 10.1089/jop.2011.0023. Epub 2011 Jul 19.

PMID:
21770740
12.

Treatment of choroidal neovascularization in pathologic myopia with intravitreal bevacizumab.

Laud K, Spaide RF, Freund KB, Slakter J, Klancnik JM Jr.

Retina. 2006 Oct;26(8):960-3. No abstract available.

PMID:
17031300
13.

Twelve-month outcome after one intravitreal injection of bevacizumab to treat myopic choroidal neovascularization.

Ruiz-Moreno JM, Montero JA, Arias L, Araiz J, Gomez-Ulla F, Silva R, Piñero DP.

Retina. 2010 Nov-Dec;30(10):1609-15. doi: 10.1097/IAE.0b013e3181e22659.

PMID:
20856171
14.

Long-term functional and morphologic retinal changes after ranibizumab and photodynamic therapy in myopic choroidal neovascularization.

Parravano M, Ricci F, Oddone F, Missiroli F, De Felici C, Varano M.

Retina. 2014 Oct;34(10):2053-62. doi: 10.1097/IAE.0000000000000201.

PMID:
24946101
15.

Comparison of visual outcome and regression pattern of myopic choroidal neovascularization after intravitreal bevacizumab or after photodynamic therapy.

Hayashi K, Ohno-Matsui K, Teramukai S, Shimada N, Moriyama M, Hayashi W, Yoshida T, Tokoro T, Mochizuki M.

Am J Ophthalmol. 2009 Sep;148(3):396-408. doi: 10.1016/j.ajo.2009.03.026. Epub 2009 May 9.

PMID:
19427991
16.

Intravitreal bevacizumab for extrafoveal choroidal neovascularization secondary to pathologic myopia.

Parodi MB, Iacono P, Papayannis A, Kontadakis S, Cascavilla ML, Zucchiatti I, Bandello F.

Retina. 2013 Mar;33(3):593-7. doi: 10.1097/IAE.0b013e31826b6731.

PMID:
23190919
17.

Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study.

Chan WM, Lai TY, Liu DT, Lam DS.

Ophthalmology. 2007 Dec;114(12):2190-6. Epub 2007 Jun 28.

PMID:
17599414
18.

Choroidal neovascularization in pathologic myopia: intravitreal ranibizumab versus bevacizumab--a randomized controlled trial.

Gharbiya M, Giustolisi R, Allievi F, Fantozzi N, Mazzeo L, Scavella V, Gabrieli CB.

Am J Ophthalmol. 2010 Mar;149(3):458-64.e1. doi: 10.1016/j.ajo.2009.10.010.

PMID:
20172072
19.

Visual acuity outcome in RADIANCE study patients with dome-shaped macular features.

Ceklic L, Wolf-Schnurrbusch U, Gekkieva M, Wolf S.

Ophthalmology. 2014 Nov;121(11):2288-9. doi: 10.1016/j.ophtha.2014.06.012. Epub 2014 Aug 8. No abstract available.

PMID:
25109929
20.

Intravitreal ranibizumab for myopic choroidal neovascularization: 12-month results.

Silva RM, Ruiz-Moreno JM, Rosa P, Carneiro A, Nascimento J, Rito LF, Cachulo ML, Carvalheira F, Murta JN.

Retina. 2010 Mar;30(3):407-12. doi: 10.1097/IAE.0b013e3181c9691e.

PMID:
20094007

Supplemental Content

Support Center